Making use of PLGA approved for clinical use by FDA, Chen et al. (2015) designed PLGA-based NPs by loaded CAT, methylene blue (MB), and black hole quencher-3 (BHQ-3) against the hypoxic tumor cells. Here, CAT is linked to neoplasm.